The Experts below are selected from a list of 2883 Experts worldwide ranked by ideXlab platform

Ramesh K. Goyal - One of the best experts on this subject based on the ideXlab platform.

  • Effect of chronic treatment with losartan on streptozotocin-induced renal dysfunction.
    Molecular and cellular biochemistry, 2003
    Co-Authors: B. Murali, Dhananjay N. Umrani, Ramesh K. Goyal
    Abstract:

    The present investigation was undertaken to study the effect of chronic treatment with angiotensin (AT1) receptor antagonist losartan (2 mg/kg, p.o., 6 weeks) on streptozotocin (STZ) induced (45 mg/kg, i.v., single dose) renal dysfunctions in diabetic rats. Injection of streptozotocin produced not only the cardinal symptoms of diabetes mellitus like loss of body weight, hyperglycemia, and Hypoinsulinemia but also the renal dysfunctions. Losartan treatment significantly prevented all these changes except STZ-induced Hypoinsulinemia. There was a significant elevation of blood pressure in diabetic rats and treatment with losartan significantly brought it back to normal. Renal dysfunction in diabetic rats was characterized by a significant decrease in creatinine clearance, elevated levels of electrolytes and renal hypertrophy. Treatment with losartan prevented these changes. A good correlation was found between biochemical parameters and histopathological abnormalities. Our data suggests that, losartan may be considered as the drug of choice when there is a co-existence of diabetes mellitus and hypertension with compromised kidney function. (Mol Cell Biochem 249: 85–90, 2003)

  • Effects of chronic treatment with cromakalim and glibenclamide in alloxan-induced diabetic rats.
    Pharmacological Research, 2002
    Co-Authors: Jayant S. Kulkarni, Anita A. Metha, Dev D. Santani, Ramesh K. Goyal
    Abstract:

    Abstract We have studied the effects of chronic treatment with cromakalim (75 ug kg−1 per day) and glibenclamide (20 mg kg−1 per day) in alloxan-induced diabetic rats. Injection of alloxan (60 mg kg−1/i.v., single dose) produced a significant increase in the blood pressure, bradycardia, hyperglycemia, Hypoinsulinemia, hyperlipidemia, hypothyroidism and depression in left ventricular developed pressure (LVDP). While glibenclamide significantly prevented alloxan-induced hyperglycemia and hypoinsulinaemia, it failed to alter hypertension, bradycardia, hypertriglyceridaemia and hypercholesterolemia. Treatment with cromakalim-prevented hypertension and bradycardia, but not the hyperglycemia or hypoinsulinaemia. Co-administration of cromakalim with glibenclamide antagonized the effect of glibenclamide on these parameters. Cromakalim treatment also prevented alloxan-induced hypercholesterolemia and hypertriglyceridaemia. It also produced a significant increase in serum T3 and T4 levels. Glibenclamide did not significantly alter alloxan-induced hypothyroidism. In conclusion our data suggest that cromakalim and glibenclamide produce some metabolic effects that are either not related to KATP channel modulation or may involve different sub-types of potassium channels. Further glibenclamide when combined with cromakalim may not be beneficial in a condition when diabetes mellitus and hypertension co-exits.

  • Effects of chronic ramipril treatment in streptozotocin-induced diabetic rats.
    Indian journal of physiology and pharmacology, 1997
    Co-Authors: Hakim Zs, Patel Bk, Ramesh K. Goyal
    Abstract:

    : The present investigation was undertaken to study the effects of chronic oral ramipril (1 mg/kg) treatment in streptozotocin (STZ) induced diabetic rats. Single tail vein injection of STZ (45 mg/kg, i.v.) produced a diabetic state exhibiting all the cardinal symptoms such as loss of body weight, polydipsia, polyuria, glucosuria, polyphagia, hypoinsulinaemia and hyperglycaemia. The diabetic state was also found to be associated with bradycardia, hypothyroidism, cardiac depression and cardiomyopathy. Ramipril treatment prevented STZ-induced hypertension, bradycardia, hypothyroidism, hyperchosesterolaemia and partially the cardiomayopathy. Ramipril treatment could not, however prevent STZ-induced loss of body weight, polyuria, polydipsia, polyphagia, hyperglycaemia, hypoinsulinaemia, hypertriglyceridaemia and cardiac depression. Our data suggests that ramipril has a few beneficial effects in the STZ-treated diabetic rats.

  • Effects Of Chronic Treatment With Nitrendipine In Streptozotocin-Induced Diabetic Rats
    Indian Journal of Pharmaceutical Sciences, 1996
    Co-Authors: S. S Joshi, T. S Shah, Ramesh K. Goyal
    Abstract:

    The present investigation involves the study of the effects chronic treatment with oral nitrendipine (15mg/kg/day) in streptozotocin (STZ) induced diabetic rats. Single tail vein injection of STZ (45 mg/kg) produced a diabetic state exhibiting all the cardinal symptoms such as loss of body weight, polyuria, polydipsia, glucosuria, Hypoinsulinemia, and hyperglycemia. The diabetic state was also found to be associated with hypothyroidism hypercholesterolemia, bradycardia, hypertension, cardiac depression and cardiomyopathy. Nitrendipine treatment prevented the hypercholesterolemia, hypertension and bradycardia observed in untreated STZ-diabetic rats. It could not prevent however, loss of body weight, hyperglycemia, Hypoinsulinemia and hypothyroidism. The cardiac depression and cardiomyopathy were found to be partially prevented by nitrendipine. These data suggests that nitrendipine has certain beneficial effects in diabetic rats.

Namita Deodhare - One of the best experts on this subject based on the ideXlab platform.

Thomas J. Hawke - One of the best experts on this subject based on the ideXlab platform.

Ramji L. Khandelwal - One of the best experts on this subject based on the ideXlab platform.

  • Does the insulin-mimetic action of vanadate involve insulin receptor kinase?
    Molecular and Cellular Biochemistry, 1993
    Co-Authors: Subbiah Pugazhenthi, Ramji L. Khandelwal
    Abstract:

    Effects of vanadate administration on the insulin receptor status in liver were examined in streptozotocin-induced diabetic rats. Diabetic rats were characterized by hyperglycemia (4-fold increase), Hypoinsulinemia (81% decrease) and a significant (P

  • Does the insulin-mimetic action of vanadate involve insulin receptor kinase?
    Molecular and cellular biochemistry, 1993
    Co-Authors: Subbiah Pugazhenthi, Ramji L. Khandelwal
    Abstract:

    Effects of vanadate administration on the insulin receptor status in liver were examined in streptozotocin-induced diabetic rats. Diabetic rats were characterized by hyperglycemia (4-fold increase), Hypoinsulinemia (81% decrease) and a significant (P < 0.01) increase in hepatic insulin receptor numbers. Autophosphorylation of the beta subunit of insulin receptor and its tyrosine kinase activity towards the synthetic peptide (poly glut4tyr1) decreased by approximately 60% as a result of diabetes. After chronic treatment of these rats with sodium orthovanadate, the plasma glucose levels were normalized to near control values with the Hypoinsulinemia remaining unaltered. The insulin-stimulated phosphorylation of the beta subunit increased significantly (P < 0.001) in diabetic rats after treatment with vanadate. However, the improvement in the tyrosine kinase activity was marginal. In vitro, vanadate prevented the dephosphorylation of the phosphorylated insulin receptor and increased its tyrosine kinase activity in the absence as well as presence of insulin. The findings of this study further support the view that insulin receptor is one of the sites involved in the insulin-mimetic actions of vanadate.

Aldrin V. Gomes - One of the best experts on this subject based on the ideXlab platform.

  • Dynamic Perturbations within the Ubiquitin Proteasome System in Diabetic Cardiomyopathy Associated with Type 1 Diabetes Mellitus
    Biophysical Journal, 2012
    Co-Authors: Shannamar Dewey, Aldrin V. Gomes
    Abstract:

    Patients with type 1 diabetes mellitus (T1DM) typically have Diabetic Cardiomyopathy (DCM) characterized by diastolic dysfunction and cardiac remodeling. The ubiquitin proteasome system (UPS) is the primary proteolytic system active in cardiac muscle protein degradation and has been shown to be activated by Hypoinsulinemia. The Akita mouse model offers a whole organism model of T1DM which develops Hypoinsulinemia and hyperglycemia in a timeline that is analogous to the human disease. Cardiac tissue from mice that were pre-diabetic (2 weeks old), recently diabetic (5 weeks old) and diabetic (12 weeks old) was analyzed. At two weeks of age, with no hyperglycemia or cardiac atrophy, proteasome caspase-like, trypsin-like and chymotrypsin-like activities were not altered. At five weeks of age, mice were hyperglycemic with decreased cardiac mass and had caspase-like and trypsin-like 26S activities that were both suppressed approximately 15%. Interestingly, protein levels of the RPT1 19S proteasome subunit were also decreased. At 12 weeks of age, the 20S caspase-like and trypsin-like activities were both increased by over 20%. Lysosomal proteases showed a marked attenuation of activity at this time point. Caspase-3 and calpain activity levels were not altered at any time. Immunoblotting of the 20S subunit PSMA6 suggests an increase in the amount of 20S proteasomes in diabetic hearts at this age. The inducible proteasome subunit, MECL-1 also increased at this time point (P